Drug News Perspect. 2009 Dec;22(10):603-8.

BRCA in breast cancer: from risk assessment to therapeutic prediction.

Diamond JR, Borges VF, Eckhardt SG, Jimeno A.

Source

Division of Medical Oncology, Department of Medicine, University of Colorado Cancer Center, University of Colorado at Denver Anschutz Medical Campus, Aurora, Colorado, USA.

Abstract

BRCA1/2 mutations are the most commonly identified germ line gene mutations in patients with hereditary breast cancer. These proteins have many critical cellular functions, including repair of DNA double-strand breaks. The role of defective BRCA1/2 as a predictor of response to DNA-damaging agents has been studied extensively in preclinical models, but prospective clinical validation is lacking. Poly [ADP-ribose] polymerase (PARP) inhibitors illustrate the concept of synthetic lethality in cells with defective BRCA1/2 and numerous PARP inhibitors are being evaluated in patients with BRCA1/2-associated tumors. BRCA1/2 mutation or functional loss will likely serve as a useful predictive biomarker of response to treatment with PARP inhibitors.

PMID:: 20140280; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Prous Science

Medical

Supplemental Content

Save items

Related citations in PubMed

The potential of PARP inhibitors in genetic breast and ovarian cancers. [Ann N Y Acad Sci. 2008]
The potential of PARP inhibitors in genetic breast and ovarian cancers.
Drew Y, Calvert H. Ann N Y Acad Sci. 2008 Sep; 1138:136-45.
Review The clinical development of inhibitors of poly(ADP-ribose) polymerase. [Ann Oncol. 2011]
Review The clinical development of inhibitors of poly(ADP-ribose) polymerase.
Calvert H, Azzariti A. Ann Oncol. 2011 Jan; 22 Suppl 1:i53-9.
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. [Lancet. 2010]
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al. Lancet. 2010 Jul 24; 376(9737):235-44. Epub 2010 Jul 6.
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2? [Breast Cancer Res. 2009]
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Frizzell KM, Kraus WL. Breast Cancer Res. 2009; 11(6):111. Epub 2009 Nov 26.
Review PARP inhibitors in breast cancer: BRCA and beyond. [Oncology (Williston Park). 2011]
Review PARP inhibitors in breast cancer: BRCA and beyond.
Rios J, Puhalla S. Oncology (Williston Park). 2011 Oct; 25(11):1014-25.

See reviews... See all...

Recent activity

Clear Turn Off Turn On

BRCA in breast cancer: from risk assessment to therapeutic prediction.
BRCA in breast cancer: from risk assessment to therapeutic prediction.
Drug News Perspect. 2009 Dec ;22(10):603-8.

PubMed
CpG methylation of a silent controlling element in the murine Avy allele is inco...
CpG methylation of a silent controlling element in the murine Avy allele is incomplete and unresponsive to methyl donor supplementation.
PLoS One. 2010 Feb 4 ;5(2):e9055.

PubMed
Reduced cul-5 activity causes aberrant follicular morphogenesis and germ cell lo...
Reduced cul-5 activity causes aberrant follicular morphogenesis and germ cell loss in Drosophila oogenesis.
PLoS One. 2010 Feb 4 ;5(2):e9048.

PubMed
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results...
Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial.
PLoS One. 2010 Feb 4 ;5(2):e9041.

PubMed
Exacerbated innate host response to SARS-CoV in aged non-human primates.
Exacerbated innate host response to SARS-CoV in aged non-human primates.
PLoS Pathog. 2010 Feb 5 ;6(2):e1000756.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: